|United States Of America||Issued Patent||10,000,582||06/19/2018||2013-127|
|European Patent Office||Published Application||2981556||02/10/2016||2013-127|
Hyaluronic acid (HyA) is a natural glycosaminoglycan (GAG) biopolymer with a variety of favorable biological properties, such as promoting cell growth, inhibiting thrombosis and modulating the tissue distribution of secreted growth factors. It is currently used in a variety of products to improve surface biocompatibility, as a substrate for tissue engineering and to control drug pharmacodynamics. A significant limiting factor for the use of HyA in medical applications is its degradation in vivo due to the high endogenous concentration of hyaluronidase and other glycolytic proteins. Depending on the tissue, the half-life of HyA can be as short as minutes, and when in contact with the blood, its half-life is approximately 1.5 hours. Therefore, current uses of HyA are limited to applications where its biomaterial properties are only required for a short duration of time.
UC Berkeley researchers have developed methods to improve the stability and half-life to HyA as well as implantable materials and drug delivery compositions containing the improved HyA. The compositions can be used in a variety of medical applications, tissue engineering, drug delivery and methods of treatment.